These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7929869)

  • 1. Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1994 Jul; 34(7):748-53. PubMed ID: 7929869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1993 Sep; 33(9):845-50. PubMed ID: 8227482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms.
    Caccia S; Confalonieri S; Guiso G; Bernasconi P; Cagnotto A; Skorupska M; Mennini T
    Psychopharmacology (Berl); 1994 Aug; 115(4):502-8. PubMed ID: 7871095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid chromatography of the potential memory-enhancing agent CL 275,838 and its main metabolites, using a post-column photochemical reactor and fluorimetric detection.
    Caccia S; Confalonieri S; Guiso G; Celeste S; Marini PP
    J Chromatogr; 1992 Oct; 581(1):109-17. PubMed ID: 1429992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
    Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
    Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.
    Beer B; Ieni JR; Wu WH; Clody D; Amorusi P; Rose J; Mant T; Gaudreault J; Cato A; Stern W
    J Clin Pharmacol; 1994 Apr; 34(4):335-44. PubMed ID: 8006201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of a Potential Antidementia Compound, CL 275,838, after Multiple Oral Doses in Patients with Dementia of Alzheimer Type or Vascular Dementia.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Tettamanti M; Tiraboschi P; Spagnoli A
    Am J Ther; 1995 Jan; 2(1):61-67. PubMed ID: 11850650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
    Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D
    J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
    Dieterle W; Mann J; Kutz K
    Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.
    Nakashima M; Uematsu T; Kosuge K; Okuyama Y; Morino A; Ozaki M; Takebe Y
    J Clin Pharmacol; 1994 Sep; 34(9):930-7. PubMed ID: 7983237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers.
    Sourgens H; Hoerr R; Biber A; Steinbrede H; Derendorf H
    J Clin Pharmacol; 1998 Apr; 38(4):373-81. PubMed ID: 9590466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.
    Mercer AJ; Lamb RJ; Hussein Z; Hobbiger S; Posner J
    Ann N Y Acad Sci; 1995 Sep; 765():324-6. PubMed ID: 7486632
    [No Abstract]   [Full Text] [Related]  

  • 17. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.
    Muirhead GJ; Faulkner S; Harness JA; Taubel J
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):37S-43S. PubMed ID: 11879258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.